Aganirsen eye drops safe well tolerated in patients with keratitis

Aganirsen eye drops demonstrated significant benefits among patients with keratitis, as well as in patients with viral keratitis and central neovascularization, according to the results of a recent study.The multicenter, double-masked, phase 3 study included 69 patients with keratitis-related progressive corneal neovascularization who were randomized to use either aganirsen drops (86 µg/day/eye) or placebo twice per day for 90 days. Patients were then followed for up to 180 days.